IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

Journal of Clinical Investigation

Volumn 118, Issue 4, 2008, Pages 1398-1404

  Zhang, Bin ^a,b,c,d   Karrison, Theodore ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; PERFORIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BYSTANDER EFFECT; CANCER IMMUNOTHERAPY; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; BYSTANDER EFFECT; CELL LINE, TUMOR; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, INTERFERON; RECEPTORS, TUMOR NECROSIS FACTOR; STROMAL CELLS; T-LYMPHOCYTES; TUMOR NECROSIS FACTORS;

EID: 41849103115     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33522     Document Type: Article

References (63)

1. Ward, P.L., Koeppen, H., Hurteau, T., and Schreiber, H. 1989. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170:217-232.
2. Boon, T., and van der Bruggen, P. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725-729.
3. Urban, J.L., Holland, J.M., Kripke, M.L., and Schreiber, H. 1982. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J. Exp. Med. 156:1025-1041.
4. Uyttenhove, C., Maryanski, J., and Boon, T. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J. Exp. Med. 157:1040-1052.
5. Ward, P.A., and Varani, J. 1990. Mechanisms of neutrophil-mediated killing of endothelial cells. J. Leukoc. Biol. 48:97-102.
6. Yee, C., et al. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99:16168-16173.
7. Marincola, F.M., Jaffee, E.M., Hicklin, D.J., and Ferrone, S. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:181-273.
8. Spiotto, M.T., Rowley, D.A., and Schreiber, H. 2004. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10:294-298.
9. Bai, X.F., Liu, J., Li, O., Zheng, P., and Liu, Y. 2003. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J. Clin. Invest. 111:1487-1496.
10. Bai, X.F., et al. 2006. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res. 66:8241-8249.
11. Nowell, P.C. 1976. The clonal evolution of tumor cell populations. Science. 194:23-28.
12. Singh, S., Ross, S.R., Acena, M., Rowley, D.A., and Schreiber, H. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139-146.
13. Ochsenbein, A.F., et al. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 96:2233-2238.
14. Ochsenbein, A.F., et al. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:1058-1064.
15. Wernert, N., Locherbach, C., Wellmann, A., Behrens, P., and Hugel, A. 2001. Presence of genetic alterations in microdissected stroma of human colon and breast cancers. Anticancer Res. 21:2259-2264.
16. Matsumoto, N., Yoshida, T., Yamashita, K., Numata, Y., and Okayasu, I. 2003. Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br. J. Cancer. 89:707-712.
17. Hu, M., et al. 2005. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37:899-905.
18. Fukino, K., Shen, L., Patocs, A., Mutter, G.L., and Eng, C. 2007. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA. 297:2103-2111.
19. Ishiguro, K., Yoshida, T., Yagishita, H., Numata, Y., and Okayasu, T. 2006. Epithelial and stromal genetic instability contributes to genesis of colorectal adenomas. Gut. 55:695-702.
20. Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. 2004. Case history: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:391-400.
21. Holash, J., et al. 2002. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99:11393-11398.
22. Nair, S., et al. 2003. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood. 102:964-971.
23. Hood, J.D., et al. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2404-2407.
24. Shaked, Y., et al. 2006. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 313:1785-1787.
25. Niethammer, A.G., et al. 2002. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8:1369-1375.
26. Lee, J., Fassnacht, M., Nair, S., Boczkowski, D., and Gilboa, E. 2005. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res. 65:11156-11163.
27. Fassnacht, M., et al. 2005. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 11:5566-5571.
28. Jubb, A.M., Oates, A.J., Holden, S., and Koeppen, H. 2006. Predicting benefit from anti-angiogenic agents in malignancy. Nat. Rev. Cancer. 6:626-635.
29. Niederman, T.M., et al. 2002. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc. Natl. Acad. Sci. U. S. A. 99:7009-7014.
30. Walsh, C.M., et al. 1994. Immune function in mice lacking the perforin gene. Proc. Natl. Acad. Sci. U. S. A. 91:10854-10858.
31. Kumar, V., Fausto, N., and Abbas, A. 2004. Neoplasia. In Robbins and Cotran pathologic basis of disease. 7th edition. V. Kumar, A. Abbas, and N. Fausto, editors. W.B. Saunders/Elsevier. Philadelphia, Pennsylvania, USA. 269-342.
32. Schreiber, K., Rowley, D.A., Riethmuller, G., and Schreiber, H. 2006. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 20:567-584.
33. Skipper, H.E. 1986. Laboratory models: some historical perspective. Cancer Treat. Rep. 70:3-7.
34. Lewin, B. 1987. Genes III. John Wiley. New York, New York, USA. 55 pp.
35. Klein, E., and Klein, G. 1972. Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and imcompatible tumor cells. Cell Immunol. 5:201-208.
36. Weissman, I.L. 1973. Tumor immunity in vivo: evidence that immune destruction of tumor leaves "bystander" cells intact. J. Natl. Cancer Inst. 51:443-448.
37. Prehn, R.T. 1973. Destruction of tumor as an "innocent bystander" in an immune response specifically directed against nontumor antigens. Isr. J. Med. Sci. 9:375-379.
38. Spiotto, M.T., et al. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 17:737-747.
39. Zhang, B., et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204:49-55.
40. Mano-Hirano, Y., et al. 1987. Inhibition of tumor-induced migration of bovine capillary endothelial cells by mouse and rabbit tumor necrosis factor. J. Natl. Cancer Inst. 78:115-120.
41. Sato, N., et al. 1986. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl. Cancer Inst. 76:1113-1121.
42. Friesel, R., Komoriya, A., and Maciag, T. 1987. Inhibition of endothelial cell proliferation by gamma-interferon. J. Cell Biol. 104:689-696.
43. Doukas, J., and Pober, J.S. 1990. IFN-gamma enhances endothelial activation induced by tumor necrosis factor but not IL-1. J. Immunol. 145:1727-1733.
44. Ruegg, C., et al. 1998. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4:408-414.
45. Nathan, C., Murray, W., Wiebe, M.E., and Rubin, B.Y. 1983. Identification of interferon-g as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158:670-681.
46. Mannel, D.N., Moore, R.N., and Mergenhagen, S.E. 1980. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect. Immun. 30:523-530.
47. Urban, J.L., Shepard, H.M., Rothstein, J.L., Sugarman, B.J., and Schreiber, H. 1986. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. U. S. A. 83:5233-5237.
48. Nathan, C.F., Murray, H.W., and Cohn, Z.A. 1980. The macrophage as an effector cell. N. Engl. J. Med. 303:622-626.
49. Poehlein, C.H., et al. 2003. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J. Immunol. 170:2004-2013.
50. Walsh, C.M., et al. 1996. Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection. J. Immunol. 156:1436-1441.
51. Qin, Z., Schwartzkopff, J., et al. 2003. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63:4095-4100.
52. Prevost-Blondel, A., Roth, E., Rosenthal, F.M., and Pircher, H. 2000. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J. Immunol. 164:3645-3651.
53. Peng, L., et al. 2000. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:7116-7124.
54. Winter, H., Hu, H.M., Urba, W.J., and Fox, B.A. 1999. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 163:4462-4472.
55. Hollenbaugh, J.A., Reome, J., Dobrzanski, M., and Dutton, R.W. 2004. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J. Immunol. 173:1738-1743.
56. Schuler, T., and Blankenstein, T. 2003. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J. Immunol. 170:4427-4431.
57. Dobrzanski, M.J., Reome, J.B., and Dutton, R.W. 2001. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98:70-84.
58. Haranaka, K., et al. 1986. Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc. Natl. Acad. Sci. U. S. A. 83:3949-3953.
59. Stoelcker, B., et al. 2000. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol. 156:1171-1176.
60. Havell, E.A., Fiers, W., and North, R.J. 1988. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167:1067-1085.
61. Takahashi, N., Fiers, W., and Brouckaert, P. 1995. Anti-tumor activity of tumor necrosis factor in combination with interferon-gamma is not affected by prior tolerization. Int. J. Cancer. 63:846-854.
62. Spiotto, M.T., and Schreiber, H. 2005. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 5:8.
63. Oehen, S., and Brduscha-Riem, K. 1998. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J. Immunol. 161:5338-5346.